Compare · ABT vs APM
ABT vs APM
Side-by-side comparison of Abbott Laboratories (ABT) and Aptorum Group Limited (APM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and APM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 35250.4x APM ($5.7M).
- ABT has been more active in the news (8 items in the past 4 weeks vs 5 for APM).
- ABT has more recent analyst coverage (25 ratings vs 0 for APM).
- Company
- Abbott Laboratories
- Aptorum Group Limited
- Price
- $116.11-0.50%
- $0.71+5.05%
- Market cap
- $200.95B
- $5.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Aptorum Group Limited
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest APM
- Amendment: Aptorum Group Limited filed SEC Form 8-K: Financial Statements and Exhibits
- Aptorum Group Limited filed SEC Form 8-K: Financial Statements and Exhibits
- New insider Arner Douglas Wayne claimed ownership of 1,062 shares (SEC Form 3)
- New insider Wu Justin Che Yuen claimed ownership of 1,832 shares (SEC Form 3)
- Aptorum Group Limited filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Mireskandari Alidad
- SEC Form SCHEDULE 13D filed by Aptorum Group Limited
- New insider Philips Laura A claimed ownership of 6,024 shares (SEC Form 3)
- New insider Sheinerman Kira claimed ownership of 1,515,293 shares (SEC Form 3)
- Aptorum Group Limited filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits